Schering-Plough 3Q Revenues: $4.6 billion (+63%)   3Q Earnings: $589.0 million (-21%) YTD Revenues: $14.2 billion (+58%) YTD Earnings: $1.3 billion (-29%) Comments: Pharmaceutical sales were $3.5 billion in the quarter (+54%) driven by Remicade sales, up 32% to $564 million, and Temodar sales, up 27% to $273 million. Nasonex sales were up 6% to $258 million. Sales of Pegintron were $235 million (+6%). Revenues for the quarter also benefited from the inclusion of $896 million of OB...